vsmira.ru editas stock news


Editas Stock News

See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Editas Medicine, Inc.'s stock symbol is EDIT and currently trades under NASDAQ. It's current price per share is approximately $ Average Recommendation, Overweight. Average Target Price, Number Of Ratings, FY Report Date, 12/ Last Quarter's Earnings, Overview. OPEN. PREV. CLOSE. VOLUME. 1,, MARKET CAP. M · DAY RANGE. – 52 WEEK RANGE. – ; Address. 11 Hurley Street. Editas Medicine, Inc. (Nasdaq: EDIT) will host a conference call and webcast on February 28, , to discuss Q4 and full-year results and provide a.

Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell $50,, of shares of its common stock in an underwritten. Editas shares jump 9% on positive news from sickle-cell study. Shares of Editas Medicine Inc. rallied % in premarket trading on Tuesday after the company. Editas Medicine Inc News ; Earnings call: Editas Medicine reports progress and strong financials in Q4 · Mar 01, ; Editas Medicine earnings beat by $ Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of. Editas Medicine (EDIT) News Today ; vsmira.ru logo · Editas Medicine (NASDAQ:EDIT) Shares Gap Up on Analyst Upgrade vsmira.ru - February 28 at AM. Editas Medicine (EDIT) PT Raised to $9 at JPMorganJPMorgan analyst Brian Cheng raised the price target on Editas Medicine (NASDAQ: EDIT) to $ (from $). Editas Medicine, Inc. · 1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. · Editas Medicine, Inc. · Insider Sells Shares of Editas Medicine Inc . View the real-time EDIT price chart on Robinhood, Editas Medicine stock live quote and latest news. Editas Medicine is a leading gene editing company focused on developing CRISPR medicines for people with serious diseases. Editas Medicine stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.

Research Editas Medicine's (Nasdaq:EDIT) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and. Get Editas Medicine Inc (EDIT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. EDIT Editas Medicine · High. · Low. · Volume. K · Open. · Pre Close. · Turnover. M · Turnover Ratio. % · P/E (Static). Loss. Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the. Stay up-to-date on Editas Medicine, Inc. Common Stock (EDIT) news with the latest updates, breaking headlines, news articles, and more from around the web. The 44 analysts offering price forecasts for Editas Medicine have a median target of , with a high estimate of and a low estimate of The median. EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today After falling 60% year to date, EDIT stock is finally reversing course and trending.

Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was. 1 Beaten-Down Stock With 55% Upside, According to Wall Street. The biotech has bounced back some in the past year. Prosper Junior. Editas Medicine Inc. ; Prev. Close. ; Low. ; 52wk Low. ; Market Cap. m ; Total Shares. m. Analyst Forecast. According to 12 analysts, the average rating for EDIT stock is "Buy." The month stock price forecast is $, which is an increase of. Explore the latest news, in-depth analysis, performance evaluation, and Q&A for Editas Medicine, Inc. (EDIT) stock. Gain valuable insights from earnings.

Editas Medicine rocketed up $ (+12%) to $ on heavy volume today. It has now risen for the past three days. The increase today helped push this month up.

best arbitrage opportunities | wechat gift card vendors

4 5 6 7 8


Copyright 2016-2024 Privice Policy Contacts SiteMap RSS